Boston Scientific

Yahoo Finance • 13 days ago

All J.P. Morgan's top stock picks for 2026

[Countdown to 2026. Loading year from 2025 to 2026. New year start concept.] SmileStudioAP J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: * Strong Financial Health: Rob... Full story

Yahoo Finance • 15 days ago

Does Boston Scientific (NYSE:BSX) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But as Peter Lynch s... Full story

Yahoo Finance • 15 days ago

Reasons to Hold Veeva Systems Stock in Your Portfolio for Now

Veeva Systems Inc. VEEV is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid third-quarter fiscal 2026 performance and strategic deals, is expected to contribute further.... Full story

Yahoo Finance • 15 days ago

U.S. Embolic Protection Devices Market and Competition Analysis, 2025-2033, Featuring Abbott Laboratories, Allium Medical Solutions, Boston Scientific, Cardinal Health and More

Company Logo Key states, including California and Texas, lead in demand due to advanced healthcare systems and aging populations U.S. Embolic Protection Device MarketU.S. Embolic Protection Device Market Dublin, Dec. 29, 2025 (GLOBE NEW... Full story

Yahoo Finance • 15 days ago

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent life-threatening condition that can oc... Full story

Yahoo Finance • 19 days ago

A Strong Growth Profile Gives Boston Scientific Corp. (BSX) a Favorable Outlook

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be downloaded here. The portfolio underperfo... Full story

Yahoo Finance • 19 days ago

What Analysts Think Is Changing In The Boston Scientific Growth Story

Boston Scientific's latest narrative update reflects only a subtle recalibration, with the fair value estimate nudging from about $126.48 to $125.86 per share as revenue growth expectations edge higher and the discount rate shifts marginal... Full story

Yahoo Finance • 20 days ago

BSX Factor-Based Stock Analysis - Peter Lynch

Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks fo... Full story

Yahoo Finance • 21 days ago

Is Fidelity Medical Equipment the Ultimate "Forever Fund" for Health Care Investors?

Key Points The health care industry took a trillion-dollar body blow from federal spending cuts in 2025, but still rose by a double-digit percentage. Its resilience comes thanks to unstoppable demographic trends in a must-have industry. O... Full story

Yahoo Finance • 22 days ago

Is Boston Scientific Corp. (BSX) Positioned for Solid, Durable Growth?

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 Index surged in the third quarter, driven by in... Full story

Yahoo Finance • last month

Notable healthcare headlines for the week: CVS, Eli Lilly and Novartis in focus

Wall Street's major averages ended lower on Friday, with the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) and the Nasdaq (COMP:IND [https://seekingalpha.com/symbol/COMP:IND]) ending the week in the red as the AI trade came under... Full story

Yahoo Finance • last month

Peter Lynch Detailed Fundamental Analysis - BSX

Below is Validea's guru fundamental report for BOSTON SCIENTIFIC CORP (BSX). Of the 22 guru strategies we follow, BSX rates highest using our P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks fo... Full story

Yahoo Finance • last month

Stocks Retreat as Bond Yields Rise

The S&P 500 Index ($SPX) (SPY) on Monday closed down by -0.35%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down by -0.45%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down by -0.25%.  December E-mini S&P futures (ESZ25) fell -0... Full story

Yahoo Finance • last month

Stocks Pressured by Higher Bond Yields

The S&P 500 Index ($SPX) (SPY) today is down -0.15%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.10%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -0.20%.  March E-mini S&P futures (ESH25) are down -0.16%, and March E-mini N... Full story

Yahoo Finance • last month

Workday Recognized as a Leader in 2025 Gartner® Magic Quadrant™ for Financial Planning Software for Fourth Year in a Row

PLEASANTON, Calif., Dec. 4, 2025 /PRNewswire/ -- Workday, Inc. (NASDAQ: WDAY), the enterprise AI platform for managing people, money, and agents, has been named a Leader in the 2025 Gartner Magic Quadrant for Financial Planning Software1 f... Full story

Yahoo Finance • last month

Principal Spectrum Tax-Advantaged Dividend Active ETF declares monthly distribution of $0.0833

* Principal Spectrum Tax-Advantaged Dividend Active ETF (PQDI [https://seekingalpha.com/symbol/PQDI]) - $0.0833 [https://www.principalam.com/us/fund/pqdi]. * Payable Dec 03, 2025; for shareholders of record Dec 01, 2025; ex-div Dec 01,... Full story

Yahoo Finance • last month

Strategic Intelligence: Medical Devices M&A Deals Report, Q3 2025 - Opportunities in Mega-deals, with a 39% Increase in Q3 2025 vs Q3 2024

Dublin, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Medical Devices M&A Deals Q3 2025 - Top Themes" report has been added to ResearchAndMarkets.com's offering. This report analyzes the disruptive themes that have d... Full story

Yahoo Finance • 2 months ago

What Could Shift the Story for Boston Scientific After Strong Results and Analyst Optimism

Boston Scientific stock remains under close watch as the company's fair value target holds steady at $126.48 per share. This reflects analysts' continued confidence following the latest results. While the discount rate saw only a marginal... Full story

Yahoo Finance • 2 months ago

Pediatric Interventional Cardiology Market Competitive Landscape Report 2025: Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue

Dublin, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The "Competitive Landscape of Pediatric Interventional Cardiology Market by Recent Developments, Strategies, Sustainability Benchmarking, Product Analysis, Key Persons and Revenue" report has bee... Full story

Yahoo Finance • 2 months ago

Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus

Wall Street staged a rebound on Friday, closing the session in positive territory after a turbulent, tech-driven downturn rattled the Nasdaq Composite just a day earlier. Friday's market boost was supported by reports that the Trump admin... Full story